Grosu Anca-Ligia, Weber Wolfgang A, Riedel Eva, Jeremic Branislav, Nieder Carsten, Franz Martina, Gumprecht Hartmut, Jaeger Ruprecht, Schwaiger Markus, Molls Michael
Department of Radiation Oncology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):64-74. doi: 10.1016/j.ijrobp.2005.01.045.
Using magnetic resonance imaging (MRI), residual tumor cannot be differentiated from nonspecific postoperative changes in operated patients with brain gliomas. The higher specificity and sensitivity of L-(methyl-11C)-labeled methionine positron emissions tomography (MET-PET) in gliomas has been demonstrated in previous studies and is the rationale for the integration of this investigation in gross tumor volume delineation. The goal of this trial was to quantify the affect of MET-PET vs. with MRI in gross tumor volume definition for radiotherapy planning of high-grade gliomas.
The trial included 39 patients with resected malignant gliomas. MRI and MET-PET data were coregistered based on mutual information. The residual tumor volume on MET-PET and the volume of tissue abnormalities on T1-weighted MRI (gadolinium [Gd] enhancement) and T2-weighted MRI (hyperintensity areas) were compared using MET-PET/MRI fusion images.
The MET-PET vs. Gd-enhanced T1-weighted MRI analysis was performed on 39 patients. In 5 patients (13%), MET uptake corresponded exactly with Gd enhancement, and in 29 (74%) of 39 patients, the region of MET uptake was larger than that of the Gd enhancement. In 27 (69%) of the 39 patients, the Gd enhancement area extended beyond the MET enhancement. MET uptake was detected up to 45 mm beyond the Gd enhancement. MET-PET vs. T2-weighted MRI was investigated in 18 patients. MET uptake did not correspond exactly with the hyperintensity areas on T2-weighted MRI in any patient. In 9 (50%) of 18 patients, MET uptake extended beyond the hyperintensity area on the T2-weighted MRI, and in 18 (100%), at least some hyperintensity on the T2-weighted MRI was located outside the MET enhancement area. MET uptake was detected up to 40 mm beyond the hyperintensity area on T2-weighted MRI.
In operated patients with brain gliomas, the size and location of residual MET uptake differs considerably from abnormalities found on postoperative MRI. Because postoperative changes cannot be differentiated from residual tumor by MRI, MET-PET, with a greater specificity for tumor tissue, can help to outline the gross tumor volume with greater accuracy.
对于接受过手术的脑胶质瘤患者,利用磁共振成像(MRI)无法区分残留肿瘤与非特异性术后改变。先前的研究已证实L-(甲基-11C)-标记的蛋氨酸正电子发射断层扫描(MET-PET)在胶质瘤中具有更高的特异性和敏感性,这也是将该检查纳入大体肿瘤体积勾画的理论依据。本试验的目的是量化MET-PET与MRI在高级别胶质瘤放疗计划的大体肿瘤体积定义中的影响。
该试验纳入了39例接受过恶性胶质瘤切除术的患者。基于互信息对MRI和MET-PET数据进行配准。使用MET-PET/MRI融合图像比较MET-PET上的残留肿瘤体积以及T1加权MRI(钆[Gd]增强)和T2加权MRI(高信号区)上的组织异常体积。
对39例患者进行了MET-PET与Gd增强T1加权MRI分析。在5例患者(13%)中,MET摄取与Gd增强完全对应,在39例患者中的29例(74%)中,MET摄取区域大于Gd增强区域。在39例患者中的27例(69%)中,Gd增强区域超出了MET增强区域。在超出Gd增强区域达45毫米处仍检测到MET摄取。对18例患者进行了MET-PET与T2加权MRI研究。在任何患者中,MET摄取与T2加权MRI上的高信号区均不完全对应。在18例患者中的9例(50%)中,MET摄取超出了T2加权MRI上的高信号区,在18例患者(100%)中,T2加权MRI上至少有一些高信号位于MET增强区域之外。在超出T2加权MRI上的高信号区达40毫米处仍检测到MET摄取。
对于接受过手术的脑胶质瘤患者,残留MET摄取的大小和位置与术后MRI发现的异常有很大差异。由于MRI无法区分术后改变与残留肿瘤,对肿瘤组织具有更高特异性的MET-PET有助于更准确地勾勒大体肿瘤体积。